Migraine is a disabling primary headache disorder that directly affects more than one billion
people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed …

Migraine affects more than one billion individuals each year across the world, and is one of
the most common neurologic disorders, with a high prevalence and morbidity, especially …

Background Primary headache disorders are common and burdensome conditions. They
are associated to several comorbidities, such as cardiovascular or psychiatric ones, which …

Migraine is a complex condition in which genetic predisposition interacts with other
biological and environmental factors determining its course. A hyperresponsive brain cortex …

Background We aimed to assess the efficacy and safety of erenumab, a fully human
monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr), for the …

Despite that it is commonly accepted that migraine is a disorder of the nervous system with a
prominent genetic basis, it is comorbid with a plethora of medical conditions. Several studies …

Background Migraine has many presumed comorbidities which have rarely been compared
between samples with and without migraine. Examining the association between headache …

Background Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide
(CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing …

Identifying highly disabled patients or at high risk of psychiatric comorbidity is crucial for
migraine management. The burden of migraine increases with headache frequency, but the …

Background Erenumab has demonstrated effectiveness for prevention of migraine attacks,
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …